Evaxion's AI Platform Shows 86% Precision in Phase 2 Cancer Vaccine Trial

summarizeSummary

This filing reports highly positive Phase 2 clinical data for Evaxion's lead personalized cancer vaccine, EVX-01, in advanced melanoma patients. The reported 86% vaccine target precision is described as "record-high" and significantly better than other methods, providing strong validation for the company's proprietary AI-Immunology™ platform. The durable immune responses and correlation between AI-prediction scores and response magnitude further reinforce the platform's effectiveness. For a clinical-stage TechBio company with a relatively small market capitalization, such robust data for a lead asset is a critical de-risking event and could significantly enhance investor confidence in its technology and pipeline. The upcoming presentation at AACR will provide further visibility.

check_boxKey Events

• Strong Phase 2 Data

  The EVX-01 personalized cancer vaccine demonstrated 86% vaccine target precision in advanced melanoma patients, a rate described as 'record-high' compared to other methods.

• AI Platform Validation

  The high success rate validates the predictive power of Evaxion's proprietary AI-Immunology™ platform in identifying therapeutically relevant vaccine targets.

• Durable Immune Response

  Two-year analysis showed durable vaccine-specific immune responses and high de novo T-cell responses following EVX-01 administration.

• AACR Presentation

  The new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 22, 2026.

auto_awesomeAnalysis

This filing reports highly positive Phase 2 clinical data for Evaxion's lead personalized cancer vaccine, EVX-01, in advanced melanoma patients. The reported 86% vaccine target precision is described as "record-high" and significantly better than other methods, providing strong validation for the company's proprietary AI-Immunology™ platform. The durable immune responses and correlation between AI-prediction scores and response magnitude further reinforce the platform's effectiveness. For a clinical-stage TechBio company with a relatively small market capitalization, such robust data for a lead asset is a critical de-risking event and could significantly enhance investor confidence in its technology and pipeline. The upcoming presentation at AACR will provide further visibility.